You just read:

Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis

News provided by

Intercept Pharmaceuticals, Inc.

Mar 31, 2011, 01:00 ET